文献速递肿瘤 PET/CT核素与放射性配体治疗

AI辅助病灶追踪对177Lu-PSMA治疗mCRPC患者PSMA PET的预后价值

Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with 177Lu-PSMA: A Retrospective, Single-Center Study.
PubMed 文献 · J Nucl Med · 2025-11-03

本研究回顾性分析20例接受177Lu-PSMA-617治疗的mCRPC患者基线与治疗结束时的68Ga-PSMA-11 PET,应用AI辅助病灶追踪生成病灶反应参数与TRAQinform Profile评分并进行生存分析。结果显示新发病灶比例越高OS越短,消失病灶比例越高OS越好,评分≥2.7者OS显著短于<2.7者。

要点

  • AI辅助病灶追踪可评估mCRPC患者177Lu-PSMA治疗的PSMA PET病灶反应。
  • 新发病灶比例越高与更短OS相关,消失病灶比例越高与更好OS相关。
  • TRAQinform Profile评分≥2.7者OS较短(10.9个月 vs 44.3个月)。

核心结论

  • AI辅助病灶追踪分析PSMA PET对接受PSMA放射性药物治疗的mCRPC患者OS具有预后价值。

研究设计与样本

  • 回顾性、单中心研究,应用TRAQinform IQ分析20例接受177Lu-PSMA-617治疗的mCRPC患者基线与治疗结束时的68Ga-PSMA-11 PET。

主要发现

  • 新发病灶比例越高与更短OS相关(风险比1.03;P=0.002)。
  • 消失病灶比例越高与更好OS相关(风险比0.98;P=0.028)。
  • TRAQinform Profile评分≥2.7者OS短于<2.7者(10.9个月 vs 44.3个月;P=0.027)。

关键数值与推荐

  • TRAQinform Profile评分阈值为2.7,≥2.7与<2.7两组OS分别为10.9个月与44.3个月(P=0.027)。

临床怎么用

  • 可考虑将AI辅助病灶追踪生成的病灶反应参数与TRAQinform Profile评分用于mCRPC患者177Lu-PSMA治疗后的预后分层。

局限性

  • 回顾性、单中心、样本量20例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to explore the prognostic value of the artificial intelligence-assisted lesion tracking applied to prostate-specific membrane antigen (PSMA) PET in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with PSMA radiopharmaceutical therapy. Methods: TRAQinform IQ was applied to baseline and end-of-treatment 68Ga-PSMA-11 PET scans from 20 patients with mCRPC treated with 177Lu-PSMA-617. Lesion response parameters and the TRAQinform Profile score-designed for early treatment response assessment-were generated. Survival analyses were performed. Results: A higher percentage of "new" lesions was associated with a shorter overall survival (OS) (hazard ratio, 1.03; P = 0.002), whereas a higher percentage of "disappeared" lesions was linked to improved OS (hazard ratio, 0.98; P = 0.028). Patients with a TRAQinform Profile score of 2.7 or greater had a shorter OS than those with a score of less than 2.7 (10.9 mo vs. 44.3 mo; P = 0.027). Conclusion: Artificial intelligence-assisted lesion-tracking analysis of PSMA PET is prognostic for OS in patients with mCRPC undergoing PSMA radiopharmaceutical therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Murthy V, Kimura K, Theus L, et al. Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with 177Lu-PSMA: A Retrospective, Single-Center Study. J Nucl Med. 2025. PMID: 40998723. doi:10.2967/jnumed.125.269971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。